Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
AIM: Prediabetes is an independent risk factor for future stroke. However, no effective treatment has yet been established for the recurrence of stroke in patients with prediabetes. Here we investigated the effects of pioglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist, for the reduction of recurrent stroke in patients with prediabetes. METHODS: Participants were patients who had a symptomatic ischemic stroke or transient ischemic attack (TIA) without a history of type 2 diabetes mellitus and who were diagnosed to have IGT or newly diagnosed diabetes by a 75-g oral glucose tolerance test. These patients were randomized to either receive or not receive pioglitazone. The primary endpoint was a recurrence of ischemic stroke. RESULTS: A total of 120 patients were enrolled in the study. Sixty-three patients received pioglitazone and 57 were enrolled in the control group that did not receive pioglitazone. The majority of patients (68.3%) were prescribed 15 mg of pioglitazone, while the remaining patients (31.7%) were treated with 30 mg of pioglitazone. Over a median follow-up period of 2.8 years, treatment with pioglitazone was found to be associated with a lower rate of the primary endpoint (recurrence of stroke) than that observed in the control group [event rate=4.8% pioglitazone vs 10.5% control, hazard ratio=0.62, 95% confidence interval 0.13-2.35, p=0.49]. However, differences were not statistically significant. CONCLUSIONS: While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158
Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke
Kernan, W. N. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.227 · Cited by 127
Ryan, K. E., McCance, D. R., Powell, L., McMahon, R., & Trimble, E. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.007 · Cited by 94
Kernan, W. N., Inzucchi, S. E., Viscoli, C. M., Brass, L. M., Bravata, D. M., Shulman, G. I., McVeety, J. C., & Horwitz, R. I. (2003) · Stroke · doi:10.1161/01.str.0000071108.00234.0e · Cited by 84
Cited by
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
“to the pioglitazone group and 2492 participants (50%) to the control group (Figure 1).(16,19,20) The study design and patient baseline characteristics of these randomized controlled trials are shown in Table 1.”
BackgroundResultZhou, Y., Huang, Y., Ji, X., Wang, X., Shen, L., & Wang, Y. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz252 · Cited by 81
Sinha, B., & Ghosal, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-72967-8 · Cited by 46
Metadata
- Authors
- Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., Furukawa, Y., Watada, H., Kawamori, R., Hattori, N., & Urabe, T.
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2015
- Volume
- 22
- Issue
- 12
- Pages
- 1305-1316
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- OpenAlex
- W1128528964
- Cited by
- 56
- References
- 10
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. https://app.cochat.ai/papers/10.5551/jat.30007
- The paper
- Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., Furukawa, Y., Watada, H., Kawamori, R., Hattori, N., & Urabe, T. (2015). Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.30007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.